Warfarin Use in Atrial Fibrillation with CKD Stage 3B

Evidence for Warfarin in Non-End-Stage CKD

Warfarin can be safely used in AF patients with moderate or moderate-to-severe CKD (GFR ≥15 mL/min), which includes CKD stage 3B 3, 1
The European Society of Cardiology recommends warfarin for AF patients with CKD stage 3B, as it has been shown to reduce stroke risk with an acceptable safety profile in this population 1, 2
The Stroke Prevention in Atrial Fibrillation (SPAF) III trial included 805 participants with stage 3 CKD and reported good outcomes with warfarin (INR 2-3) 1
A large Swedish database showed that stroke risk was lower in CKD patients with AF treated with warfarin (adjusted HR 0.76; 95% CI 0.72-0.80), although bleeding risk was slightly increased, especially during therapy initiation 1
A meta-analysis of 13 observational studies (>48,500 patients) found that in patients with AF and non-end-stage CKD, warfarin was associated with lower risk of ischemic stroke/thromboembolism (HR 0.70; 95% CI 0.54-0.89) 6

Regular monitoring of renal function is essential for all patients on anticoagulants, especially those with CKD 1, 7
Good quality anticoagulation control (Time in Therapeutic Range >65-70%) is recommended when using warfarin in CKD patients 8
The American College of Chest Physicians recommends careful monitoring of bleeding risk in all warfarin users with renal disease (HR 1.33; 95% CI 1.16-1.53) 4, 5

The European Heart Society suggests that NOACs (Novel Oral Anticoagulants) may be an alternative option for patients with CKD stage 3B: 3, 1, 2
A meta-analysis of major NOAC trials showed that patients with mild or moderate CKD suffered fewer strokes, systemic emboli, and major bleeding events on NOACs than on warfarin 1

While warfarin is beneficial in non-dialysis CKD (including stage 3B), it is not recommended for routine use in patients with end-stage kidney disease (ESKD) on dialysis: 4, 6, 5
For CKD stage 3B specifically, the benefit of stroke reduction outweighs the bleeding risk with warfarin 4, 5

For moderate CKD (Stage III, CrCl 30-59 mL/min), which includes stage 3B, oral anticoagulation is suggested in patients with a CHA₂DS₂-VASc score ≥2 using either label-adjusted NOACs or dose-adjusted vitamin K antagonists like warfarin 8
The American College of Chest Physicians recommends that for moderate CKD, oral anticoagulation decisions and treatments should match those of patients without CKD 8
Regular monitoring of kidney function is essential to refine risk estimation and adjust therapy as needed 1, 7